Founder & CEO
Helle Funch Nielsen
In 2003 Helle founded Exhalation Technology Ltd with the purpose of developing a device to screen for inflammatory conditions in the airways of horses. In 2006/2007 the scope of Exhalation Technology was extended to also include humans. Today the main focus of Exhalation Technology is in humans.
Prior to her start-ups Helle has experience working for Fisons Pharmaceuticals (1991-94), Fisons/Rhone Poulenc Rorer (1994-99), for Alcon (1999-2000) and for Galderma Products (2000-01).
Director Strategy & Business Development
Stig Lytke Brejl
Stig has been with Exhalation Technology since 2012. His focus has been on strategy development and implementation, but during his years at Exhalation Technology he has also gained substantial insight in and practical experience with MedTech product development, quality assurance and regulatory approval. In parallel to his job at Exhalation Technology, Stig has assumed the role as Chairman of the Board at OSAA Innovation, a small Danish start-up developing a mobile solution for IV-therapy.
Consultant Finance Director
Neil has spent more than 25 years in the medical technology market, with a track record of success in driving business development and growth, via sales and marketing, domestic and international distributor management, market access, major accounts, new business integration, and change management, gained in the UK and in export within an SME and leading MedTech company environment.
Senior Director, Business Development
David comes to Exhalation Technology with more than 25 years of demonstrated success in Medical sales, sales management and business development experience. Most recently he has been consulting with several start-up medical device companies in the respiratory device space. Prior to that he worked more than 10 years with Aerocrine helping to establish the NIOX FeNO device a the gold standard in respiratory drug development research programs.